Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5720836 | 1.00 | TSHR (0.49) | TSHRTDP1L3MBTL1LMNANPC1 | |
| SCHEMBL1138690 | 0.91 | LMNA (0.49) | LMNASMN1; SMN2KMT2AALDH1A1CHRM2 | |
| SCHEMBL5720971 | 0.91 | LMNA (0.49) | LMNASMN1; SMN2KMT2AALDH1A1CHRM2 | |
| SCHEMBL27682265 | 0.91 | LMNA (0.49) | LMNASMN1; SMN2KMT2AALDH1A1CHRM2 | |
| SCHEMBL5720898 | 0.87 | SMN1; SMN2 (0.45) | TSHRTDP1L3MBTL1LMNANPC1 | |
| SCHEMBL23191566 | 0.86 | TSHR (0.53) | TSHRTDP1L3MBTL1LMNANPC1 | |
| SCHEMBL5720835 | 0.85 | L3MBTL1 (0.48) | TSHRTDP1L3MBTL1LMNANPC1 | |
| SCHEMBL5720923 | 0.85 | SLC2A1 (0.43) | TSHRTDP1L3MBTL1LMNANPC1 | |
| SCHEMBL5720899 | 0.85 | FAAH (0.48) | L3MBTL1LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5720925 | 0.85 | FAAH (0.47) | TSHRTDP1L3MBTL1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178433-A1 | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto | UBE INDUSTRIES, LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1361279-B1 | Method for enzymatic production of enantiomerically enriched beta amino acids | DEGUSSA (DE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1621529-A1 | 3-AMINO-3-ARYLPROPIONIC ACID n-ALKYL ESTERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF THE ANTIPODES THERETO | Ube Industries, Ltd. (JP) | 2006-02-01 | — | — | EP | disclosed |
| US-6987010-B2 | Process for the enzymatic preparation of enantiomer-enriched β-amino acids | DEGUSSA AG (DE) | 2006-01-17 | — | — | US | disclosed |
| US-20050142646-A1 | Process for the enzymatic preparation of enantiomer-enriched beta-amino acids | DEGUSSA AG | 2005-06-30 | — | — | US | disclosed |
| US-6869781-B2 | Process for the enzymatic preparation of enantiomer-enriched β-amino acids | DEGUSSA AG (DE) | 2005-03-22 | — | — | US | disclosed |
| US-20040029236-A1 | Process for the enzymatic preparation of enantiomer-enriched beta-amino acids | DEGUSSA AG | 2004-02-12 | — | — | US | disclosed |
| EP-1361279-A1 | Method for enzymatic production of enantiomerically enriched beta amino acids | Degussa AG (DE) | 2003-11-12 | — | — | EP | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| EP-0542708-B1 | Substituted beta-amino acid derivatives useful as platelet aggregation inhibitors | MONSANTO CO (US) | 2001-05-30 | — | — | EP | disclosed |
| EP-0843967-B1 | Use of Beta-aminopropionic acid derivatives as fungicides | ISAGRO RICERCA SRL (IT) | 2000-04-05 | — | — | EP | disclosed |
| US-5856311-A | Derivatives of β-aminopropionic acid with a fungicidal activity | ISAGRO RICERCA SRL (IT) | 1999-01-05 | — | — | US | disclosed |
| EP-0843967-A1 | Use of Beta-aminopropionic acid derivatives as fungicides | ISAGRO RICERCA S.r.l. (IT) | 1998-05-27 | — | — | EP | disclosed |
| EP-0718280-A2 | Derivatives of beta-aminopropionic acid with a fungicidal activity | ISAGRO RICERCA S.r.l. (IT) | 1996-06-26 | — | — | EP | disclosed |
| EP-0614360-A1 | SUBSTITUTED -g(b)-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS. | SEARLE & CO (US) | 1994-09-14 | — | — | EP | disclosed |
| WO-1993007867-A1 | SUBSTITUTED β-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178433-A1 | 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto | ALAD, ARSA, ALDH7A1 | TSHR 800/4885TDP1 4084/4885L3MBTL1 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.